Home Immunology & Inflammation Fungal 억제제 Cycloheximide

연구용

Cycloheximide 단백질 합성 억제제

제품 번호S7418

Cycloheximide는 항진균성 항생제로, 생체 내 단백질 합성 및 RNA 합성의 IC50이 각각 532.5 nM 및 2880 nM인 진핵생물 단백질 합성 억제제입니다. Cycloheximide는 페로프토시스를 억제하고 자가포식을 억제합니다.Cycloheximide (NSC-185)는 Dysmnesia 동물 모델을 유도하는 데 사용될 수 있습니다.용액은 불안정하므로 신선하게 준비해야 합니다.본 제품은 위험 화학물질(급성 독성/인화성/피부 부식성)입니다. 보호 안면 마스크, 장갑 및 의류를 착용하고 사용하십시오.
Cycloheximide Fungal 억제제 Chemical Structure

화학 구조

분자량: 281.35

바로가기

품질 관리

배치: 순도: 99.96%
99.96

세포 배양, 처리 및 작업 농도

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
CEM Anticancer assay Tested in vitro for anticancer activity against CEM cells, IC50 = 0.12 μM. 10072683
9L Anticancer assay Tested in vitro for anticancer activity against 9L cells, IC50 = 0.2 μM. 10072683
SK-MEL-28 Anticancer assay Tested in vitro for anticancer activity against SK-MEL-28 cells, IC50 = 1 μM. 10072683
Vero Cytotoxicity assay Tested in vitro for cytotoxicity against Vero cells, IC50 = 1.2 μM. 10072683
LNCaP Anticancer assay Tested in vitro for anticancer activity against LNCaP cells, IC50 = 1.2 μM. 10072683
MCF-7 Anticancer assay Tested in vitro for anticancer activity against MCF-7 cells, IC50 = 1.5 μM. 10072683
PBM Cytotoxicity assay Tested in vitro for cytotoxicity against PBM cells, IC50 = 2.1 μM. 10072683
HepG2 Anticancer assay Tested in vitro for anticancer activity against HepG2 cells, IC50 = 2.5 μM. 10072683
SK-MES-1 Anticancer assay Tested in vitro for anticancer activity against SK-MES-1 cells, IC50 = 2.7 μM. 10072683
PC-3 Anticancer assay Tested in vitro for anticancer activity against PC-3 cells, IC50 = 3.5 μM. 10072683
Jurkat T-cells Function assay Inhibitory concentration against Human Jurkat T cells, IC50 = 0.93 μM. 10212121
Jurkat T-cells Function assay Inhibitory concentration against Human Jurkat T cells, IC80 = 1.54 μM. 10212121
Jurkat T-cells Function assay 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.93 μM. 11052798
Jurkat T-cells Function assay 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC80 = 1.54 μM. 11052798
CEM Cytotoxicity assay Cytotoxicity was determined in CEM cells, relative to RVT, IC50 = 0.08 μM. 15081000
PBM Cytotoxicity assay Cytotoxicity was determined in PBM cells, relative to RVT, IC50 = 0.46 μM. 15081000
Vero Cytotoxicity assay Cytotoxicity was determined in Vero cells, relative to RVT, IC50 = 0.53 μM. 15081000
HeLa Function assay Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay, IC50 = 0.036 μM. 15974627
medulloblastoma cells Antiproliferative assay Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay, EC50 = 0.042 μM. 17417631
neural precursor cells Antiproliferative assay Antiproliferative activity against mouse neural precursor cells by colony formation assay, EC50 = 0.054 μM. 17417631
astrocyte cells Antiproliferative assay Antiproliferative activity against mouse astrocyte cells by MTT assay, EC50 = 0.071 μM. 17417631
neural precursor cells Antiproliferative assay Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50 = 0.142 μM. 17417631
HeLa Cytotoxicity assay 24 hrs Cytotoxicity against human HeLa cells after 24 hrs, CD50 = 0.1 μM. 18394884
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.912 μM. 18771242
HeLa Function assay 2 hrs Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5325 μM. 20118940
HeLa Function assay 2 hrs Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 2.8801 μM. 20118940
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 20356064
BESM Function assay 88 hrs Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50 = 0.4 μM. 20547819
NIH/3T3 Cytotoxicity assay 48 hrs Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay, IC50 = 1.1 μM. 21899268
MDA-MB-231 Cytotoxicity assay 48 hrs Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 1.2 μM. 21899268
AGS Cytotoxicity assay 48 hrs Cytotoxicity against human AGS cells after 48 hrs by MTT assay, IC50 = 3.6 μM. 21899268
HT-29 Cytotoxicity assay 48 hrs Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 12.8 μM. 21899268
HepG2-A16-CD81 Function assay 10 uM NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration, IC50 = 0.0781 μM. 22096101
3T3 Cytotoxicity assay 72 hrs Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 22437110
HepG2 Function assay HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 0.047 μM. 22586124
PA1 Cytotoxicity assay 24 hrs Cytotoxicity against human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. 23202484
PA1 Growth inhibition assay 24 hrs Growth inhibition of human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. 28011220
3T3 Cytotoxicity assay Cytotoxicity against mouse 3T3 cells by SRB assay, IC50 = 0.3 μM. 29247859
CEM Cytotoxicity assay 5 days Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay, IC50 = 0.2 μM. 29778528
Vero Cytotoxicity assay 3 days Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay, IC50 = 0.2 μM. 29778528
3T3 Cytotoxicity assay 48 hrs Cytotoxicity against rat 3T3 cells after 48 hrs by MTT assay, IC50 = 0.61 μM. 30146096
MCF7 Function assay 10 ug/mL 1 hr Inhibition of HIF1alpha RNA translation in human MCF7 cells at 10 ug/mL pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis 22607231
AGS Apoptosis assay 150 ug/mL 48 hrs Induction of apoptosis in human AGS cells assessed as early apoptosis level at 150 ug/mL after 48 hrs by Annexin V-FITC apoptosis assay 21899268
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells 29435139
T47D Function assay 10 uM 4 hrs Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting 15974627
T47D Function assay 0.3 uM 4 hrs Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting 15974627
T47D Function assay 3 uM 16 hrs Inhibition of hypoxia-induced HIF1 activation in human T47D cells at 3 uM after 16 hrs by luciferase reporter gene assay 15974627
T47D Function assay 0.7 uM 16 hrs Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells at 0.7 uM after 16 hrs by luciferase reporter gene assay 15974627
T47D Function assay 10 uM 16 hrs Inhibition of hypoxia-induced VEGF expression in human T47D cells at 10 uM after 16 hrs by ELISA 15974627
T47D Function assay 0.3 uM 4 hrs Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting 15974627
T47D Function assay 10 uM 4 hrs Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting 15974627
neural precursor cells Function assay 3 uM Induction of neurosphere phenotype changes in mouse neural precursor cells at 3 uM 17417631
HeLa Cytotoxicity assay Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis 18066055
HeLa Function assay Inhibition of mitosis in human HeLa cells by imaging analysis 18066055
HEK293T Function assay 50 uM 30 mins Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 50 uM after 30 mins by spectrophotometry 20118940
T47D Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human T47D cells at 10 uM after 48 hrs by SRB assay 23434131
MDA-MB-231 Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay 23434131
NCI-H460 Function assay 10 ug/mL up to 9 hrs Reduction of HSP1 stability in human NCI-H460 cells assessed as protein degradation at 10 ug/mL up to 9 hrs by Western blot analysis 24746225
HeLa Cytotoxicity assay 25 uM 18 hrs Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay 25028062
RAW264.7 Function assay 70 uM 6 hrs Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 70 uM after 6 hrs by luciferase reporter gene assay 25667960
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량 281.35 화학식

C15H23NO4

 보관 (수령일로부터) 3 years-20°C powder
CAS 번호 66-81-9 -- 원액 보관

동의어 NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80 Smiles CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C

용해도

In vitro
배치:

DMSO : 56 mg/mL (199.04 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 56 mg/mL

Water : 15 mg/mL

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

시험관 내(In vitro)

단백질 합성 억제제인 Cycloheximide는 포스파티딜세린 노출 및 세포자멸사/괴사로 인한 ΔΨm 손실을 약화시켜 GSIV 유도 숙주 세포 사멸을 감소시킵니다.
생체 내(In vivo)

이 화합물은 단백질 합성 억제제로, 단백질 합성 억제의 2차적인 결과로 기억 형성 조절자를 변경하여 기억에 작용합니다.
참조
  • [4] https://pubmed.ncbi.nlm.nih.gov/30916348/

적용 분야

방법 바이오마커 이미지 PMID
Western blot β-catenin / MSX2 LIFR / gp130 / TfR BIP / P-P70S6K / P62 / ATF4 / Actin / LC3-I / LC3-II CYP87A3 ERK3 / IRP2
S7418-WB-1
12095419
RNA blot PDI-2 / tubulin / rRNA LEF1 / Cyc-D1 / IGF-1 / HGF / VEGF / KGF / GAPDH
S7418-RNA-1
18713834
Immunofluorescence SCD6 / DHH1 / XRNA α-eIF3 / α-Dcp1 TUNEL Rpl25 / Nhp6 β-Catenin
S7418-IF-1
18713834

임상시험 정보

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT03700788 Not yet recruiting
Apical Periodontitis
University of Southern California
 May 30 2023 Phase 3
NCT05506566 Recruiting
Tumor|Positron-Emission Tomography
First Affiliated Hospital of Fujian Medical University
 May 1 2022 Phase 1|Phase 2
NCT02202304 Withdrawn
Periodontal Disease|Caries
Rosa Moreno Lopez|Ivoclar Vivadent AG|University of Aberdeen
 September 10 2017 Phase 4
NCT01521325 Completed
Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer
Morphotek
 September 2011 Phase 1
NCT02168374 Completed
Dental Caries
Aline R F de Castilho|Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas Brazil
 March 2008 Phase 2

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

이름을 입력해주세요.
이메일을 입력해주세요. 유효한 이메일 주소를 입력해주세요.
저희에게 무엇이든 작성해주세요.